Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bayer A.G. (OTC: BAYZF).

Full DD Report for BAYZF

You must become a subscriber to view this report.

Recent News from (OTC: BAYZF)

Monthly Dividend Stocks Discounts Worldwide - August 2018
Welcome to the August edition of "Monthly Dividend Stock Discounts Worldwide". Contrary to the US edition, this one covers dividend stocks from outside the US with at least 10% discount in the last month. The purpose is to identify potential bargains for dividend investors. As you surely know,...
Source: SeekingAlpha
Date: September, 06 2018 10:50
Bayer A.G. (BAYZF) CEO Werner Baumann on Q2 2018 Results - Earnings Call Transcript
Bayer A.G. (BAYZF) Q2 2018 Earnings Conference Call September 5, 2018 8:00 AM ET Executives Oliver Maier - Head of Investor Relations Werner Baumann - Chief Executive Officer Wolfgang Nickl - Chief Financial Officer Dieter Weinand - Pharmaceuticals Heiko Schipper - Consumer H...
Source: SeekingAlpha
Date: September, 05 2018 15:37
Bayer A.G. 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Bayer A.G. in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: September, 05 2018 13:58
Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital
The stock markets never stop to amaze me. While July was heavily driven by concerns about a deteriorating trade war, August, in general, was a big rally, with markets hitting new highs and the euro dropping down to as low as $1.13. Overall net capital spending was around $2,650 as I divested...
Source: SeekingAlpha
Date: September, 03 2018 02:53
1 Easy Step To Beat The Market
Today’s Market The S&P 500 ( SPY ) hit an all-time high today. Where does that leave its value? Its market cap is now 146% of GDP – a price that historically offers a prospective -2% annual return. The CAPE ratio is at 33, 94% above its historical average of 17. The prosp...
Source: SeekingAlpha
Date: August, 22 2018 09:30
Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2)
In my previous article on Loxo Oncology ( LOXO ), I introduced the challenges facing LOXO as they transition to becoming a commercial-stage biotech company. In that article, I discuss their R&D strategy, scientific platform, and upcoming clinical and regulatory milestones. In this art...
Source: SeekingAlpha
Date: August, 17 2018 15:54
Progenics Pharmaceuticals (Part II): Explicating The Ramifications Of The Azedra Approval
I have never taken a single course in economics, nor tried to make a single dollar, ever, from foreseeing macroeconomic changes. - Charlie Munger Progenics Pharmaceuticals (NASDAQ: PGNX ) is a highly interesting life science company that is approaching its “growth inflection, ...
Source: SeekingAlpha
Date: August, 12 2018 23:42
U.S. Moats Ahead Despite IT Underweight
For the month Ending July 30, 2018 Performance Overview Domestic moat companies, as represented by the Morningstar Wide Moat Focus IndexSM ( MWMFTR, or "U.S. Moat Index" ), once again posted strong results in July, outperforming the S&P 500 Index (4.11% vs. 3.72%, respectively) and pul...
Source: SeekingAlpha
Date: August, 09 2018 07:58
Dividend Portfolio Review: Busy Earnings Season, Heavy Buying, Growing Dividends
More ups and downs in July with earnings season hitting its peak and trade threats and denials coming in every couple of days led to accelerated buying culminating in around $4,400 in fresh capital deployed. Earnings season often triggers some remarkable selloffs and rallies but this time I...
Source: SeekingAlpha
Date: August, 07 2018 08:55
Greenlight Capital's (David Einhorn) Q2 2018 Letter
Read more ...
Source: SeekingAlpha
Date: August, 01 2018 11:03


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BAYZF.

About Bayer A.G. (OTC: BAYZF)

Logo for Bayer A.G. (OTC: BAYZF)

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high tech materials. At the same time Bayer creates value through innovation, growth and improved earning power. Bayer HealthCare AG researches, develops, manufactures and markets innovative products for disease prevention, diagnosis and treatment. Bayer CropScience AG is a global leader in crop protection and non agricultural pest control. Bayer MaterialScience AG is a renowned supplier of high performance materials and innovative system solutions used in a wide range of products for everyday life. The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible corporate citizen, economy, ecology and social responsibility are corporate policy objectives of equal rank.




Current Management

  • Dr. Marijn Dekkers / CEO
  • Werner Wenning / CFO
  • Martin Eisenhauer / Securities Counsel
  • Peter Dahlhoff / IR

Current Share Structure

  • Market Cap: $98,133,895,426 - 05/11/2018
  • Issue and Outstanding: 826,947,800 - 03/31/2011


Daily Technical Chart for (OTC: BAYZF)

Daily Technical Chart for (OTC: BAYZF)

Stay tuned for daily updates and more on (OTC: BAYZF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BAYZF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BAYZF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BAYZF and does not buy, sell, or trade any shares of BAYZF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: